EOFLOW

EOFlow Seeks Global Partnership at ‘2022 German-Korean Business Forum in KAIST’

EOFlow Co., Ltd., a provider of wearable drug delivery solutions, has announced today that it presented a session and had business partnership meetings at '2022 German-Korean Business Forum in KAIST'. The forum was held by the Ministry of Science and ICT (MSIT), KAIST (Korea Advanced Institute of Science & Technology), KAIST Global Commercialization Center (KAIST GCC), and German-Korean Business Forum (GKBF) in KAIST main campus in Daejeon city. Research professors from KAIST, internationally renowned healthcare companies from Germ...

Jun. 16. 2022
[DB Financial Investment] Diabetes market and company report on EOFlow

Dear investors, DB Financial Investment has published an analyst report today on June 14th. Senior researcher Jay Yoo in healthcare/growth industry covers rapidly growing global diabetes market and devices in glucose diagnosis to glucose management in the report. Analyst Yoo introduced EOFlow as a company of interest. He mentioned that after the Company's domestic launch of the world's second wearable disposable insulin pump "EOPatch" to be commercially available in 2021, he is looking forward to the European lau...

Jun. 14. 2022
EOFlow Announces First Patient Enrolled in the Pivotal Study of Two-Part Wearable Artificial Pancreas “EOPatch X” on People with Type 1 Diabetes in Korea

▶ “EOPatch X” is a two-part wearable artificial pancreas (AP) solution that automatically adjusts insulin delivery based on the user’s glucose level ▶ A multicenter trial that will be conducted at nine university-hospitals and will enroll over one hundred people with type 1 diabetes aims to validate the clinical efficacy and safety of “EOPatch X” EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company) today announced that the first patient has been enrolled in the pivotal study of two-part wearable artificial pa...

May. 20. 2022
EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’

▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it officially launches iOS Version of ‘Narsha,’ a smartphone application for wearable insulin pump in Korea. It has been nine months since the Company officially launched the Android application of Narsha. Narsha is the world’s first...

May. 17. 2022
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue

▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced its Q1 financial results ended on March 31, 2022. EOFlow announced its consolidated financial results: first quarter of 2022 revenue of 949 million Korean...

May. 16. 2022
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal

▶ A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus ▶ 4-week treatment with EOPatch was safe and led to clinically meaningful improvement in glycemic control compared to those with MDI or conventional insulin pump EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its first clinical study results on the wearable insulin pump EOPatch in patients with type 1 diabetes were publ...

Apr. 11. 2022
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE

▶ A Major Export Deal for EOFlow’s Innovative Insulin Pump EOPatch EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced on March 31 that it has signed a contract with GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) to supply 48.8 billion Korean won (40 million US dollar) worth of EOPatch, a disposable and wearable insulin pump, over the course of five years. The Company said the contract amount is equivalent to 7043 percent (%) of its entire sales last year. T...

Apr. 04. 2022
EOFlow Announces Board Member Change to Sharpen its Focus on the US Market

▶ Mr. Luis Malave will put more focus on the US market as EOFlow’s US president ▶ EOFlow will appoint Mr. CJ Kim as a new board member Mar. 10, 2022 - EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), wearable healthcare company, announced on March 8th that the Company’s board member Mr. Luis Malave had resigned from the board on January 31st. Mr. Malave is the president of EOFlow, Inc. (EOFlow US), a wholly owned subsidiary of EOFlow Co., Ltd. in the US, and has been serving as a board member of EOFlow since 2...

Mar. 10. 2022
EOFlow Holds a Clinical Researcher Meeting for its Two-Part Wearable Artificial Pancreas “EOPatch X” on People with Type 1 Diabetes in Korea

▶ “EOPatch X” is a two-part wearable artificial pancreas (AP) solution that automatically adjusts basal insulin delivery based on the user’s glucose level ▶ EOFlow shows commitment to support for successful completion of clinical trial EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company) has announced that the Company held a clinical researcher meeting for its pivotal study of two-part wearable artificial pancreas “EOPatch X” on people with type 1 diabetes in Korea. The researcher meeting was held at O...

Mar. 07. 2022
[Edaily news] Analysis on EOFlow company and business

EOFlow's founding CEO Jesse Kim's interview articles were published at edaily on March 4th. Mr. Kim explained fully from company history to the long-term plan. For the full 3 articles, please see the link below (in Korean only): 1. Top-tier global team- MIT graduate founding CEO and executives from the world's No.1 competitor https://pharm.edaily.co.kr/news/read?newsId=01554726632259712&mediaCodeNo=257 2. Accelerating the development of wearable artificial pancreas (AP) with a goal to provide end-to-end smart care solut...

Mar. 04. 2022
[Edaily CEO interview] Reasons to invest in EOFlow

EOFlow's founder and CEO Jesse Kim had an interview with edaily on February 16. He announced EOFlow's plan to enter the U.S. market with its current disposable wearable insulin pump 'EOPatch'. The Company will begin its submission process to the Food and Drug Administration (FDA) as early as first half of the year, and commercially launch the product next year. ‘EOPatch’ was fully launched in South Korea in April and the Company expanded its reach to Europe, starting with the first shipment completed in September. ...

Feb. 18. 2022
EOFlow Reports Full Year 2021 Revenue Increase of 3102% Year-Over-Year

▶ EOFlow released its consolidated financial statements for the full year of 2021: Revenue of 693 million KRW, Operating loss of 26.9 billion KRW, Net loss of 29.4 billion KRW. ▶ Revenue growth from full launch in Korea (April) and shipment to Europe (September). ▶ Menarini will progressively launch the product in Europe from 2022 onwards. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a wearable healthcare company, announced its provisional financial statements for the full year of 2021 on February 14th, 2022, after the close...

Feb. 15. 2022
EOFlow Successfully Raises 113.4 Billion Korean Won to Establish a Foothold to Become a Global Healthcare Leader

▶113.4 billion Won raised with new common stock offering, followed by a 2:1 stock split ▶Secured long-term growth momentum ▶Aims to focus on global wearable insulin pump market and expand to wearable healthcare market segments EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a wearable healthcare company, has announced today that the Company successfully raised 113.4 billion Won and completed 2:1 stock split. The Company newly issued 3,000,000 shares of common stocks, representing 25.99% of the previous shares outstanding thro...

Feb. 08. 2022
[MoneyToday] EOFlow with wearable drug delivery challenges obesity treatment market worth 5 billion USD

EOFlow CEO's interview article was published today at MoneyToday. He explained EOFlow's newly established joint venture 'SanPlena' aims to develop innovative wearable drug delivery solutions for treatment of Obesity & NASH. Zihipp, a spin out from Imperial College London, is led by highly respected Prof. Sir Stephen R. Bloom who is well known as a seminal figure in creation of the hormone-based diabetes and obesity treatment market. Zihipp has developed several new peptide dr...

Feb. 03. 2022
EOFlow Declares Commitment To ESG & Ethical Management Policy

▶ Establishes Code of Ethics EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that its leadership team held a ceremony at Seohyeon office on January 17 to formally pledge to proactively practice ESG and ethical management. EOFlow’s founder and CEO Jesse Kim and executives met to declare management policy firmly based on ESG and code of ethics. With this declaration, the Company intends to increase ethical awareness and action by employees as well...

Jan. 19. 2022

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here